July 31, 2014 — A radiation expert from the University of Texas MD Anderson Cancer Center can now add innovator and entrepreneur to his list of accomplishments following the conception and development of a new device approved by the U.S. Food and Drug Administration (FDA) for prostate cancer.

Understanding that the use of precise and accurate equipment is a prerequisite for good outcomes, Steven Frank, M.D., invented the first permanently implantable magnetic resonance imaging (MRI) marker, a novel technology designed to help improve the assessment of prostate cancer patients and post-treatment monitoring. Following FDA approval last fall, MD Anderson began implanting the marker this past March.

The idea for the marker came during Frank’s fellowship, when he became interested in using MRI scans for prostate brachytherapy. “Given MRI’s specific capabilities, however, the implanted seeds appeared as ‘black holes’ and couldn’t be clearly seen by physicians. Although the problem wasn’t new, no one was trying to solve it,” he said.

After much experimentation, Frank discovered that cobalt-chloride complex contrast (C4) agents lit up on MRI and would eliminate the ‘black hole.’ “By using the marker, radiologists now have a superior ability to adjust radiation dosages appropriately,” said Frank.

Although he lacked formal business training, in 2008 Frank founded C4 Imaging LLC to manufacture and market the marker, efforts overseen by a seasoned CEO with industry experience. Frank remains involved, raising funds and securing grants for ongoing research.

From the outset, Frank credits mentors at MD Anderson – all veteran scientists and inventors – who helped him navigate the complex FDA regulatory requirements and other protocols.

“I found myself balancing a dual career life – one as a practicing physician and another as an entrepreneur. It was challenging,” said Frank, also husband and a father of four daughters. “Throughout the experience, however, I remained positive that this development would improve the quality of care and ultimately offer prostate cancer patients greater chance of survival.”

Frank’s story is emblematic of a new trend of physician-scientist-entrepreneurs, who are eager to spur innovation, transform medicine and improve patients’ lives. The rise in the number of “entrepreneur doctors” has led to the establishment of the Society of Physician Entrepreneurs, with a mission to provide “support networks” to business-minded doctors.

For more information: www.c4imaging.com


Related Content

News | Radiology Imaging

Aug. 12, 2025 – Medical imaging methods such as ultrasound and MRI are often affected by background noise, which can ...

Time August 12, 2025
arrow
News | Artificial Intelligence

July 22, 2025 — GE HealthCare has topped a U.S. Food and Drug Administration (FDA) list of AI-enabled medical device ...

Time July 23, 2025
arrow
News | Prostate Cancer

July 16, 2025 — Artificial intelligence can improve diagnostic consistency and reduce false-positives in prostate cancer ...

Time July 22, 2025
arrow
Feature

A new study published in JCO Clinical Cancer Informatics tackles a critical challenge in cancer diagnostics: ensuring ...

Time July 01, 2025
arrow
News | Prostate Cancer

June 26, 2025 – Quibim, a global provider of quantitative medical imaging solutions, has launched AI-QUAL, a new feature ...

Time June 26, 2025
arrow
News | Pediatric Imaging

April 10, 2025 — Cincinnati Children’s and GE HealthCare will form a strategic research program focused on driving ...

Time April 10, 2025
arrow
News | Radiology Imaging

Jan. 15, 2025 — University of California, San Francisco (UCSF) Department of Radiology & Biomedical Imaging and GE ...

Time January 27, 2025
arrow
News | Contrast Media

Jan. 10, 2025 – Bayer has announced positive topline results of the Phase III QUANTI studies evaluating the efficacy and ...

Time January 14, 2025
arrow
News | Women's Health

Aug. 19, 2024 — GE HealthCare recently announced a collaboration with the University of California San Diego School of ...

Time August 29, 2024
arrow
News | Radiology Business

July 25, 2024 — Immunis, Inc., a clinical-stage biotech developing groundbreaking secretome therapeutics for age and ...

Time July 25, 2024
arrow
Subscribe Now